Clearmind Medicine shares are trading lower. The company announced the signing of a new research agreement to examine MEAI in combination and sequencing with tirzepatide against GLP-1 medications.

Benzinga Newsdesk www.benzinga.com Positive 67.7%

Neg 0% Neu 0% Pos 67.7%

Comments

No comments yet. Be the first!